KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Charles River Laboratories International (CRL) Long-Term Debt Issuances (2016 - 2025)

Charles River Laboratories International has reported Long-Term Debt Issuances over the past 16 years, most recently at $156.7 million for Q4 2025.

For Q4 2025, Long-Term Debt Issuances rose 49.5% year-over-year to $156.7 million; the TTM value through Dec 2025 reached $1.2 billion, up 13.49%, while the annual FY2025 figure was $1.2 billion, 13.49% up from the prior year.
Long-Term Debt Issuances for Q4 2025 was $156.7 million at Charles River Laboratories International, up from $107.5 million in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $3.0 billion in Q2 2021 and troughed at $51.2 million in Q3 2023.
A 5-year average of $649.5 million and a median of $428.3 million in 2024 define the central range for Long-Term Debt Issuances.
Biggest five-year swings in Long-Term Debt Issuances: skyrocketed 111972800.0% in 2021 and later crashed 92.67% in 2023.
Year by year, Long-Term Debt Issuances stood at $831.4 million in 2021, then tumbled by 81.51% to $153.8 million in 2022, then soared by 188.31% to $443.3 million in 2023, then crashed by 76.36% to $104.8 million in 2024, then surged by 49.5% to $156.7 million in 2025.
Business Quant data shows Long-Term Debt Issuances for CRL at $156.7 million in Q4 2025, $107.5 million in Q3 2025, and $547.0 million in Q2 2025.